| 7.48 -0.12 (-1.58%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.84 | 1-year : | 11.5 |
| Resists | First : | 8.43 | Second : | 9.84 |
| Pivot price | 7.08  |
|||
| Supports | First : | 6.97 | Second : | 6.07 |
| MAs | MA(5) : | 7.78  |
MA(20) : | 6.96 |
| MA(100) : | 7.61 |
MA(250) : | 9.98 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.8 |
D(3) : | 72.8 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 18.79 | Low : | 5.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RNAC ] has closed below upper band by 33.4%. Bollinger Bands are 29.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.54 - 7.58 | 7.58 - 7.61 |
| Low: | 7.06 - 7.1 | 7.1 - 7.14 |
| Close: | 7.42 - 7.48 | 7.48 - 7.54 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Mon, 02 Mar 2026
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Thu, 26 Feb 2026
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Mon, 23 Feb 2026
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Tue, 03 Feb 2026
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Fri, 09 Jan 2026
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire
Thu, 18 Dec 2025
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 9.29e+006 (%) |
| Held by Institutions | 60.7 (%) |
| Shares Short | 2,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.108e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 660.6 % |
| Return on Equity (ttm) | -12.7 % |
| Qtrly Rev. Growth | 1.09e+006 % |
| Gross Profit (p.s.) | 40.97 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.26244e+008 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.23 |
| Dividend | 0 |
| Forward Dividend | 2.16e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|